SCHEMBL1612752

SCHEMBL1612752

CC(=O)c1cn(S(=O)(=O)c2ccc(C)cc2)c2ccc(Br)cc12

nearest known ligand 0.55

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
AKR1C3 P42330 1/20 0.53
AKR1C1 Q04828 1/20 0.53
ALOX5 P09917 5/20 0.47
HTR6 P50406 9/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
PTGS2 P35354 1/20 0.46
KDM4E B2RXH2 1/20 0.45
UBE2N P61088 1/20 0.45
KLK7 P49862 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
ALK Q9UM73 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20424529 0.91 AKR1C3 (0.64) LMNASMN1; SMN2AKR1C3AKR1C1ALOX5
SCHEMBL946621 0.89 LMNA (0.71) LMNASMN1; SMN2AKR1C3AKR1C1HTR6
SCHEMBL23219219 0.87 MEN1 (0.58) LMNASMN1; SMN2AKR1C3AKR1C1ALOX5
SCHEMBL31748353 0.87 ALOX5 (0.50) LMNASMN1; SMN2AKR1C3AKR1C1ALOX5
SCHEMBL19839201 0.86 AKR1C3 (0.49) LMNASMN1; SMN2AKR1C3AKR1C1ALOX5
SCHEMBL12748673 0.84 AKR1C3 (0.68) LMNASMN1; SMN2AKR1C3AKR1C1ALOX5
SCHEMBL31571431 0.83 HTR6 (0.55) AKR1C3AKR1C1HTR6CYP3A4CYP2D6
SCHEMBL23589255 0.83 HTR6 (0.55) AKR1C3AKR1C1HTR6CYP3A4CYP2D6
SCHEMBL28504095 0.82 HTR6 (0.49) AKR1C3AKR1C1ALOX5HTR6CYP3A4
SCHEMBL16205467 0.82 LMNA (0.49) LMNASMN1; SMN2AKR1C3AKR1C1ALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11672780-B2 [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2023-06-13 US disclosed
US-20180000790-A1 [1,2,4]TRIAZOLO[1,5-a]PYRIDINYL SUBSTITUTED INDOLE COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY 2018-01-04 US disclosed
EP-2315751-A1 ALKYNYL ALCOHOLS AS KINASE INHIBITORS Amgen Inc. (US) 2011-05-04 EP disclosed
US-20110086834-A1 ALKYNYL ALCOHOLS AS KINASE INHIBITORS AMGEN INC. (US) 2011-04-14 US disclosed
US-20110086834-A1 ALKYNYL ALCOHOLS AS KINASE INHIBITORS AMGEN INC. (US) 2011-04-14 US disclosed
US-20110086834-A1 ALKYNYL ALCOHOLS AS KINASE INHIBITORS AMGEN INC. (US) 2011-04-14 US disclosed
WO-2009158011-A1 ALKYNYL ALCOHOLS AS KINASE INHIBITORS AMGEN INC. (US) 2009-12-30 WO disclosed
WO-2009158011-A1 ALKYNYL ALCOHOLS AS KINASE INHIBITORS AMGEN INC. (US) 2009-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11672780-B2 [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds TLR7, TLR1, TLR5 LMNA 2619/4885SMN1; SMN2 4357/4885AKR1C3 1215/4885
US-20180000790-A1 [1,2,4]TRIAZOLO[1,5-a]PYRIDINYL SUBSTITUTED INDOLE COMPOUNDS TLR7, TLR1, TLR5 LMNA 2619/4885SMN1; SMN2 4357/4885AKR1C3 1215/4885
US-20110086834-A1 ALKYNYL ALCOHOLS AS KINASE INHIBITORS NFKBIA, MAP3K1, MAP3K2 LMNA 2017/4885SMN1; SMN2 2966/4885AKR1C3 318/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.